239 related articles for article (PubMed ID: 22190252)
1. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
[TBL] [Abstract][Full Text] [Related]
3. Advances in the treatment of invasive neonatal candidiasis.
Botero-Calderon L; Benjamin DK; Cohen-Wolkowiez M
Expert Opin Pharmacother; 2015 May; 16(7):1035-48. PubMed ID: 25842986
[TBL] [Abstract][Full Text] [Related]
4. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Glöckner A
Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
6. Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
Ericson J; Manzoni P; Benjamin DK
Early Hum Dev; 2013 Jun; 89 Suppl 1(0 1):S25-7. PubMed ID: 23809344
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
Liu X; Liu D; Pan Y; Li Y
J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
[TBL] [Abstract][Full Text] [Related]
8. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.
Lempers VJ; Schouten JA; Hunfeld NG; Colbers A; van Leeuwen HJ; Burger DM; Verweij PE; Pickkers P; Brüggemann RJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4403-9. PubMed ID: 25963988
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.
Sharma D; Vazquez JA
Expert Opin Pharmacother; 2024 Mar; 25(4):339-347. PubMed ID: 38497379
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.
Hope WW; Kaibara A; Roy M; Arrieta A; Azie N; Kovanda LL; Benjamin DK
Antimicrob Agents Chemother; 2015 Feb; 59(2):905-13. PubMed ID: 25421470
[TBL] [Abstract][Full Text] [Related]
11. Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.
Epstein DJ; Seo SK; Brown JM; Papanicolaou GA
J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i60-i72. PubMed ID: 29304213
[TBL] [Abstract][Full Text] [Related]
12. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications.
Autmizguine J; Guptill JT; Cohen-Wolkowiez M; Benjamin DK; Capparelli EV
Drugs; 2014 Jun; 74(8):891-909. PubMed ID: 24872147
[TBL] [Abstract][Full Text] [Related]
14. Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit.
Watt KM; Cohen-Wolkowiez M; Williams DC; Bonadonna DK; Cheifetz IM; Thakker D; Benjamin DK; Brouwer KLR
J Extra Corpor Technol; 2017 Sep; 49(3):150-159. PubMed ID: 28979038
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.
Grau S; Pozo JC; Romá E; Salavert M; Barrueta JA; Peral C; Rodriguez I; Rubio-Rodríguez D; Rubio-Terrés C
Clinicoecon Outcomes Res; 2015; 7():527-35. PubMed ID: 26508881
[TBL] [Abstract][Full Text] [Related]
16. Insight into advances for the biosynthetic progress of fermented echinocandins of antifungals.
Jiang K; Luo P; Wang X; Lu L
Microb Biotechnol; 2024 Jan; 17(1):e14359. PubMed ID: 37885073
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal beyond clinical guidelines for intraabdominal candidiasis.
Maseda E; Martín-Loeches I; Zaragoza R; Pemán J; Fortún J; Grau S; Aguilar G; Varela M; Borges M; Giménez MJ; Rodríguez A
Crit Care; 2023 Oct; 27(1):382. PubMed ID: 37789338
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.
Wiederhold NP; Herrera LA
Clin Med Insights Pediatr; 2012; 6():19-31. PubMed ID: 23641163
[TBL] [Abstract][Full Text] [Related]
19. Treatment and prophylaxis of invasive candidiasis.
Tripathi N; Watt K; Benjamin DK
Semin Perinatol; 2012 Dec; 36(6):416-23. PubMed ID: 23177800
[TBL] [Abstract][Full Text] [Related]
20. The use of echinocandins in hospitalized children in the United States.
Downes KJ; Ellis D; Lavigne S; Bryan M; Zaoutis TE; Fisher BT
Med Mycol; 2019 Jul; 57(5):534-541. PubMed ID: 30265325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
